Lung Cancer Treatment in India for International Patients: Options, Costs & 2026 Guide

Lung cancer is the leading cause of cancer death globally, and it's also among the most scientifically complex to treat — the correct treatment is now inseparable from molecular profiling. Two patients with identical-looking tumours may require completely different therapies depending on their genetic mutations. India's major thoracic oncology centres have invested heavily in molecular diagnostics, VATS surgical capability, and access to targeted agents and immunotherapy, making them a realistic destination for international patients who need modern treatment and can't access or afford it locally.

TL;DR: VATS lobectomy (surgery for early-stage lung cancer) costs USD 8,000–14,000 in India. Targeted therapy runs USD 1,500–4,000/month depending on the agent. Immunotherapy (pembrolizumab) costs USD 4,000–7,000 per cycle. Stereotactic body radiotherapy (SBRT) costs USD 5,000–8,000. India's top centres offer full biomarker profiling before treatment (Patients Beyond Borders, 2024).

How Is Lung Cancer Staged and Classified in India?

The first priority at any Indian thoracic oncology centre is accurate staging. Many patients arrive with a diagnosis but incomplete staging — which means the treatment plan is incomplete too.

Standard staging workup includes:

• CT chest, abdomen, and pelvis with IV contrast — assesses tumour size, lymph node involvement, and distant metastases
• PET-CT — the most sensitive tool for identifying mediastinal node involvement and distant spread; standard at major Indian centres
• MRI brain — essential for small-cell lung cancer (SCLC) staging and in NSCLC with neurological symptoms
• EBUS (endobronchial ultrasound) — allows biopsy of mediastinal lymph nodes without surgery when nodes are enlarged on CT
• Bronchoscopy — for central tumours
• CT-guided biopsy — for peripheral lesions not accessible via bronchoscopy

Staging is followed immediately by molecular profiling (see next section), as the two together determine the complete treatment pathway.

Biomarker Testing: Why It's Essential Before Treatment

Lung cancer treatment in 2026 cannot be planned without molecular profiling. Non-small cell lung cancer (NSCLC) — which accounts for approximately 85% of all lung cancers — is now stratified by genetic alteration, not just histology.

Indian thoracic centres perform comprehensive biomarker panels:

• EGFR mutation (exons 18–21) — present in 30–40% of Asian patients; directs use of EGFR TKIs (gefitinib, erlotinib, osimertinib)
• ALK rearrangement — present in 5–7% of NSCLC; responds to alectinib or crizotinib
• ROS1 rearrangement — rare but highly targetable with crizotinib or entrectinib
• KRAS G12C mutation — targetable with sotorasib
• BRAF V600E — targetable with dabrafenib/trametinib combination
• PD-L1 expression — determines eligibility for pembrolizumab monotherapy (high PD-L1) or combination immunochemotherapy
• MET exon 14 skipping — targetable with capmatinib

Next-generation sequencing (NGS) panels covering 50–500 genes are available at Apollo, Fortis, and Medanta — identifying all actionable alterations in a single test from the biopsy tissue.

Surgical Options: VATS vs Open Thoracotomy

For Stage I and II NSCLC with resectable tumours, surgery is the treatment of choice. Modern thoracic surgery in India is predominantly VATS (video-assisted thoracic surgery), also called minimally invasive thoracic surgery.

VATS lobectomy removes the affected lobe through 3–4 small incisions and a utility incision, without spreading the ribs. Compared to open thoracotomy, VATS delivers equivalent oncological outcomes (5-year survival, margin status, lymph node dissection quality) with:

• Hospital stay of 3–5 days vs 7–10 days for open surgery
• Significantly less post-operative pain
• Faster return to full activity
• Lower complication rates

Robotic VATS is available at Apollo Delhi, Fortis Memorial, and Medanta, offering superior ergonomics for complex hilar dissections.

Open thoracotomy is reserved for bulky central tumours, complex hilar involvement, and cases requiring chest wall resection or pneumonectomy.

Costs Across Treatment Types

Treatment	India (USD)	USA (USD)	UK Private
VATS lobectomy	8,000 – 14,000	40,000 – 100,000	£20,000 – £50,000
Open thoracotomy / pneumonectomy	10,000 – 18,000	50,000 – 120,000	£25,000 – £65,000
SBRT / SABR (5–10 fractions)	5,000 – 8,000	20,000 – 50,000	£10,000 – £25,000
Targeted therapy (per month)	1,500 – 4,000	10,000 – 20,000	£5,000 – £12,000
Immunotherapy (per cycle)	4,000 – 7,000	15,000 – 30,000	£8,000 – £20,000
Chemotherapy (per cycle)	800 – 1,800	5,000 – 15,000	£2,000 – £8,000

Sources: Patients Beyond Borders 2024; Arodya hospital quotes 2025.

Targeted therapy and immunotherapy are ongoing monthly costs — patients who achieve good responses may continue for 12–24 months or longer. Many patients begin systemic therapy in India and continue at home with the same regimen, purchasing drugs locally or arranging supply from India where generic versions are significantly cheaper.

For a broader overview of oncology services available to international patients, see our oncology guide.

Stage-by-Stage Treatment Approach

Stage I–II (early, resectable): Surgery is the primary treatment. VATS lobectomy ± mediastinal lymph node dissection. Adjuvant chemotherapy (cisplatin-based) for Stage II tumours with high-risk features. Targeted therapy if EGFR+ or ALK+ in the adjuvant setting after surgery.

Stage III (locally advanced): Treatment depends on whether the mediastinal nodes are resectable. Resectable Stage IIIA: surgery after induction chemotherapy. Unresectable Stage IIIB/C: concurrent chemoradiation (cisplatin + etoposide with 60 Gy radiation) followed by consolidation durvalumab immunotherapy.

Stage IV (metastatic): Systemic therapy is the mainstay. If a driver mutation is present, targeted therapy is first-line. If no driver mutation: pembrolizumab monotherapy (if PD-L1 >50%) or pembrolizumab + chemotherapy combination. Small-cell lung cancer: carboplatin + etoposide ± immunotherapy.

Oligometastatic disease (1–3 metastases): SBRT to the primary plus stereotactic radiosurgery to brain/adrenal metastases, combined with systemic therapy — a strategy that's increasingly producing durable responses in NSCLC with driver mutations.

Radiotherapy for Lung Cancer in India

India's top centres use modern radiotherapy platforms — Varian TrueBeam, Elekta Versa HD — with 4D imaging capability to account for respiratory motion during treatment planning.

SBRT (stereotactic body radiotherapy) delivers ablative doses to early-stage inoperable tumours in 5–10 fractions over 1–2 weeks. Particularly important for patients with COPD, cardiac disease, or other comorbidities making surgery high-risk. Local control rates exceed 90% at 3 years for Stage I NSCLC treated with SBRT at experienced Indian centres.

For a detailed guide to radiotherapy technology and protocols in India, see our radiation therapy guide.

What Staging Documents to Bring

Bring everything you have. Indian oncologists review imaging before ordering repeats — if your CT or PET-CT was done within 8 weeks, it may be accepted. Older imaging will typically be repeated. Bring:

• All CT, PET-CT, and MRI reports with images (CD or digital transfer)
• Pathology report from biopsy (with immunohistochemistry if available)
• Biomarker testing results (EGFR, ALK, PD-L1) if already done
• Full blood count, LFTs, renal function, LDH
• Spirometry (essential before thoracic surgery to assess lung function reserve)
• Any previous treatment records (chemotherapy, radiation)

When you're ready to explore lung cancer treatment in India, submit your staging documents and imaging to Arodya. We'll have the thoracic oncology team review your case and provide a complete treatment proposal with costs before you travel.